Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, single arm study evaluating the safety and
efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with
unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who
received at least 2 prior treatments, at least 1 in the metastatic setting.